Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
about
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceOlder patients with myeloma derive similar benefit from autologous transplantation.Time-dependent endpoints as predictors of overall survival in multiple myelomaAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Review of health-related quality of life data in multiple myeloma patients treated with novel agents.Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidatesPatterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based studyNovel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agentsThalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.Potential therapeutic benefits of strategies directed to mitochondria.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Proteasome inhibitors in the treatment of multiple myelomaPrognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival.Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyCyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.IMWG consensus on maintenance therapy in multiple myeloma.European perspective on multiple myeloma treatment strategies: update following recent congressesDiagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group.Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maiThe outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Senior adult oncology.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyTotal marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012Front line treatment of elderly multiple myeloma in the era of novel agents.Initial therapy in multiple myeloma: investigating the new treatment paradigm.International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.Current multiple myeloma treatment strategies with novel agents: a European perspective
P2860
Q26767418-B91F67DB-FBBC-4B0B-9108-BE5458A2007AQ28077567-D0D14683-48E2-4E6F-A64E-291B51E802E8Q30370038-8B1ABD2A-2D96-4341-9D6B-A74CF80FA483Q30538040-B1FD0F9A-C258-4EB3-9067-9EE4928EDBBDQ30595175-045C26CD-DAA9-422E-938E-89DD2A2DE4B3Q30650394-55D1972D-4043-44CF-8911-628FBE23E010Q33387733-9B786D91-59C3-4CE9-8B19-CB284F779B01Q33639796-0411FECD-C84B-471E-8D9E-734C5B136CEEQ33710588-AD85FB1E-F869-4669-921B-415861563633Q33886073-E197C76A-131B-41E0-AD4A-44295A055D6FQ34095653-9906C3C6-A9F2-4F6F-8573-29C8BD843E57Q34117168-BB00EC16-9B0D-4376-A6B8-ABE53153EC4EQ34372086-19055ACA-9036-4C6C-90D4-9DD616F4A9D2Q34604658-9FED9799-D972-4691-832B-47D4EC803D81Q34611676-C08B5D6B-9D4E-43D7-9FFC-5E32ACFD3E25Q34647698-4699273B-E644-4A33-8442-92906118E85AQ35061518-FEF3CC0B-0077-4336-87B7-C2582013486AQ35153760-5635A2D5-CE76-4AA2-ACFC-AE0F7E3F8A2FQ35266125-A41C5A7C-EB5E-4A84-A6A5-5E8DF0DCF4EEQ35794472-8572616E-0AC2-4197-A94E-7051F6264F01Q35802414-E66F7056-D368-47F4-B413-61639F0BA697Q35876966-862F7620-DAC5-429F-BCE8-9E9FB852023CQ35989943-635B8313-C2D4-407E-8EF3-A0F42596E065Q36301287-06563C7A-CAE2-42A5-95C1-26B6BD650F46Q36331737-D0542008-0788-42FD-80ED-B77FFC33D096Q36536365-942C48C1-93D4-4E2D-9F89-509423043996Q36565628-43864A98-78C6-4C56-8801-1B11A3043542Q36706899-68FADC4C-8762-45E7-AE0B-71AB361A49A7Q36777233-03FEF213-EE48-4B84-8632-A38ABA8F7AE8Q36851424-15CC8188-90A8-44E3-BE08-79A112DD0E0EQ36963203-91124B6C-4FA4-4A84-87BA-7F1A54F50642Q37030249-C9E0449B-4E8E-4485-9F21-169F028EDCB3Q37057028-96B1B013-E359-4D24-9856-DA16338D32B3Q37303213-AD7CB742-BD2D-4530-831D-880DAD527A27Q37411805-02BA3C3D-7D08-4F9A-BFF6-E6B6AC756B1BQ37507513-2C6B266A-10CF-46DB-8CF9-70907BEF6682Q37530452-A34A2FF4-F22D-4F06-8F07-514C2465FE99Q37536148-58894382-6B06-499F-8508-42B2042578D6Q37546023-8D086FB5-84F2-4A31-B3DC-6712B3E6452FQ37677935-698CD8EA-2DA1-4559-B473-DF559869B045
P2860
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Oral melphalan, prednisone, an ...... a randomized controlled trial.
@en
Oral melphalan, prednisone, an ...... a randomized controlled trial.
@nl
type
label
Oral melphalan, prednisone, an ...... a randomized controlled trial.
@en
Oral melphalan, prednisone, an ...... a randomized controlled trial.
@nl
prefLabel
Oral melphalan, prednisone, an ...... a randomized controlled trial.
@en
Oral melphalan, prednisone, an ...... a randomized controlled trial.
@nl
P2093
P50
P1433
P1476
Oral melphalan, prednisone, an ...... a randomized controlled trial
@en
P2093
Anna M Liberati
Antonietta Falcone
Antonio Capaldi
Daniele Derudas
Fausto Dore
Giulia Benevolo
Marco Montanaro
Mario Boccadoro
Patrizia Falco
Renato Zambello
P304
P356
10.1182/BLOOD-2008-04-149427
P407
P50
P577
2008-05-27T00:00:00Z